Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 3 study of sebetralstat in children with hereditary angioedema
MOH_2024-10-14_013347Phase 3Completed
- Sponsor
- KalVista Pharmaceuticals
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of sebetralstat in hereditary angioedema (HAE), sponsored by KalVista Pharmaceuticals. Primary endpoints: Safety, Pharmacokinetics and 1 more. Started Oct 2024; status: completed.
02
Drugs
sebetralstat
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on MOH_2024-10-14_013347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-10-14_013347.